Michael Rachlin

Michael Rachlin co-leads the Life Sciences practice within the Corporate Finance segment, specializing in assisting clients in the biopharmaceutical, medical technology and cannabis industries evaluate transaction opportunities and larger growth-related initiatives, as well as valuation, deal modeling and strategic alternatives. Mr. Rachlin has approximately 20 years of experience advising life sciences clients through their most critical transaction and transformation challenges.

Mr. Rachlin provides complex transaction, financial modeling, valuation and financial advisory services for a variety of strategic planning, acquisition planning, restructuring, litigation and financial and tax reporting purposes. He has experience delivering customized solutions across the M&A and restructuring lifecycles, including target screening, diligence, structuring, purchase accounting and post-merger integration. He designs and delivers custom solutions that address the financial needs of both large and middle-market life sciences organizations.

Prior to joining FTI Consulting, Mr. Rachlin was a senior leader at Deloitte Transactions & Business Analytics, LLP, where he oversaw a range of transaction and financial advisory services for the firm’s middle-market life sciences segment, including strategy, planning, go-to-market and delivery.

Mr. Rachlin is an adjunct professor at Brooklyn Law School where he teaches financial modeling, valuation and finance. Michael previously sat on the Finance Committee at BioNJ, where he focused on financial topics for pharmaceutical companies and is a frequent speaker at industry conferences including JPM Healthcare and BioMed Israel.

Relevant Experience:

• Led the development of enterprise-wide and asset-based sum-of-the-parts valuation analyses (pipeline and commercial products) for several global publicly traded life sciences companies to help inform executive and board of directors decision making and strategic alternatives
• Provided transaction advisory services on more than 50 biopharmaceutical transactions; transaction sizes range from $50 million to $65 billion
• Proving expert witness support and litigation support on an active life sciences M&A dispute
• Provided in and out of court financial advisory restructuring services for various life sciences companies and creditors
• Led the valuation of more than 300 global legal entities of a global biopharmaceutical organization to support its tax and management planning activities.
• Led the valuation of various intellectual property (“IP”) assets of a biopharmaceutical company to drive tax efficiencies and management planning